Bioactive peptides and proteins are the focus of many medical applications, but they have some disadvantages as drugs. They are rapidly hydrolyzed with loss of biological activities. Furthermore, proteins derived from non-human species are often antigenic. To overcome these disadvantages, protein hybrids with natural and artificial polymers have been studied. Among various polymers, poly(ethylene glycol) (PEG) has been used for preparation of hybrids with biologically-active proteins, since PEG has low toxicity, low immunogenicity and good solubility in both aqueous and organic solvents. Pegylation (hybrid formation with PEG) of proteins has been well documented and pegylated adenosine deamidase 2) and interferon 3) are used in clinical therapeutics. In contrast, relatively few studies have focused on the pegylation of small peptides. This may be based upon the assumption that modification of a small bioactive peptide with a large molecule such as PEG would result in a loss of activity. However, we prepared PEG hybrids of laminin-and fibronectin-related peptides and proved that PEG is also a promising drug carrier for bioactive small peptides. 4, 5) These PEG hybrids were pegylated at the carboxyl terminal of the peptides. Site-specific pegylation of large proteins is difficult but site-specific pegylation of relatively small peptides is possible by careful selection of synthetic strategies. Lu and Felix 6) succeeded in the site-specific pegylation of an interleukin-related peptide. Furthermore, PEG can function as a flexible spacer, linking 2 functional groups that allow a structural conformation for optimal biological activity. We designed an amino acid type PEG (aaPEG) as a novel peptide carrier to prepare multivalent PEG-peptide hybrids. We were successful in forming bivalent PEG hybrids of fibronectin-and laminin-related peptides (Arg-Gly-Asp-aaPEG-Glu-IleLeu-Asp-Val and Pro-Asp-Ser-Gly-Arg-aaPEG-Tyr-IleGly-Ser-Arg) 7, 8) which have two active sites in each protein. Here, we report the preparation and biological activity of a bivalent poly(ethylene glycol) hybrid containing an active site (Arg-Gly-Asp, RGD) and its synergistic site (Pro-HisSer-Arg-Asn, PHSRN) of fibronectin.
Bioactive peptides and proteins are the focus of many medical applications, but they have some disadvantages as drugs. They are rapidly hydrolyzed with loss of biological activities. Furthermore, proteins derived from non-human species are often antigenic. To overcome these disadvantages, protein hybrids with natural and artificial polymers have been studied. Among various polymers, poly(ethylene glycol) (PEG) has been used for preparation of hybrids with biologically-active proteins, since PEG has low toxicity, low immunogenicity and good solubility in both aqueous and organic solvents. Pegylation (hybrid formation with PEG) of proteins has been well documented and pegylated adenosine deamidase 2) and interferon 3) are used in clinical therapeutics. In contrast, relatively few studies have focused on the pegylation of small peptides. This may be based upon the assumption that modification of a small bioactive peptide with a large molecule such as PEG would result in a loss of activity. However, we prepared PEG hybrids of laminin-and fibronectin-related peptides and proved that PEG is also a promising drug carrier for bioactive small peptides. 4, 5) These PEG hybrids were pegylated at the carboxyl terminal of the peptides. Site-specific pegylation of large proteins is difficult but site-specific pegylation of relatively small peptides is possible by careful selection of synthetic strategies. Lu and Felix 6) succeeded in the site-specific pegylation of an interleukin-related peptide. Furthermore, PEG can function as a flexible spacer, linking 2 functional groups that allow a structural conformation for optimal biological activity. We designed an amino acid type PEG (aaPEG) as a novel peptide carrier to prepare multivalent PEG-peptide hybrids. We were successful in forming bivalent PEG hybrids of fibronectin-and laminin-related peptides (Arg-Gly-Asp-aaPEG-Glu-IleLeu-Asp-Val and Pro-Asp-Ser-Gly-Arg-aaPEG-Tyr-IleGly-Ser-Arg) 7, 8) which have two active sites in each protein. Here, we report the preparation and biological activity of a bivalent poly(ethylene glycol) hybrid containing an active site (Arg-Gly-Asp, RGD) and its synergistic site (Pro-HisSer-Arg-Asn, PHSRN) of fibronectin.
Fibronectin, a glycoprotein, is a multifunctional extracellular matrix protein. It plays an important biological role in many cell-surface interactions, mediating cell adhesion, embryonic cell migration, and wound healing. 9, 10) Among the many active sites in extracellular matrix proteins, the cell-adhesive domain of fibronectin has been well studied.
11) An RGD sequence located in the 10th type III repeating unit is a critical cell-adhesive site for the cell-surface receptor integrin, 11, 12) and a PHSRN sequence in the 9th type III repeating unit, although itself not biologically active, enhances the celladhesive activity of RGD. [13] [14] [15] However, the cell-adhesive activity of a recombinant protein corresponding to the 10th type III repeating unit of fibronectin is not stimulated by a PHSRN peptide. Based upon this evidence, the spatial array between PHSRN and RGD is important for a synergistic interaction. 15) We designed a bivalent PEG hybrid, PHSRN-aaPEG-RGD, in which aaPEG functions as a spacer between two functional peptides. aaPEG [H 2 NCH 2 CH 2 NHCOCH 2 -(OCH 2 CH 2 ) n OCH 2 COOH] was prepared from commercial poly(oxyethylene)diglycolic acid 3000 (carboxymethylated PEG, cmPEG. average MW 2500-3400).
16) The flexible conformation of PEG may allow the two functional groups to bind properly. As shown in Fig. 2 , the PEG hybrid, PHSRNaaPEG-RGD, was prepared on a Rink amide resin 17) using a Fmoc-based solid-phase strategy.
18) The Fmoc groups were removed by treatment with 20% piperidine/dimethylformamide (DMF) for 20 min. Coupling reactions were performed by the diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt) method. 19) The side chains of amino acids were protected as follows: His and Asn by a trityl (Trt) group; Ser 20) Since the coupling reaction of Fmoc-aaPEG-OH was slow, it was preincubated with DIC and HOBt at 0°C for 1 h and allowed to be used in a coupling reaction. The reaction was repeated once to completion. Fmoc-aaPEG-Arg(Pmc)-GlyAsp(OBu t )-Rink amide resin (prepared by the manual method) was treated with 20% piperidine/DMF to form the H-aaPEG-Arg(Pmc)-Gly-Asp(OBu t )-Rink amide resin, followed by treatment with trifluoroacetic acid (TFA)/thioanisole/ethanedithiol (94/3/3). The resulting aaPEG-RGD was purified by HPLC on a DAISOPAK SP-120-5-ODS-B column (DAISO Co., Ltd.).
After introduction of Fmoc-aaPEG-OH on the resin, the deprotection reaction of the Fmoc group with piperidine became slow and quantitative measurement of deprotection could not be determined by the Kaiser test (ninhydrin test). 21) Therefore, synthesis of PHSRN-aaPEG-RGD was performed by an automatic peptide synthesizer (ABI 433A) which facilitated monitoring the deprotection reaction after introduction of Fmoc-aaPEG on the resin. The deprotection reaction could be monitored by the peptide synthesizer, measuring the conductivity of the solvent from the deprotection reaction mixture. Synthetic Fmoc-Pro- The cell spreading activity of the PEG hybrids (aaPEG-RGD, PHSRN-PEG, and PHSRN-aaPEG-RGD) was examined, using Baby Hamster Kidney (BHK) cells as described previously. 13) Fibronectin was used as a positive control. Fibronectin was most effective in terms of cell spreading activity (Fig. 3) . The aaPEG-RGD hybrid displayed cell spreading activity but PHSRN-PEG lacked significant activity. These findings are comparable to previous results obtained using synthetic peptides.
15) The PHSRN-aaPEG-RGD peptide had a greater cell spreading activity than aaPEG-RGD, suggesting that PHSRN synergistically enhances the cellular activity of RGD in the PEG-bridged compounds. These observations are comparable to previous results obtained using recombinant proteins. 15) Thus, aaPEG is potentially useful as a spacer and support matrix that allows the binding of functional peptides. Recently many biologically active sequences have been identified in extra-cellular matrix proteins. 22) Some of the active peptides may synergistically interact with cellular receptors, 23) thus, the bivalent aaPEG hybrid method may be useful for enhancing the synergistic interactions of these peptides.
Since peptides containing the RGD sequence were reported to be inhibitors of experimental metastasis, 12) RGDpeptides are a focus for development of anti-cancer drugs. The anti-metastatic effect of PHSRN-aaPEG-RGD on experimental metastasis was examined in mice. Prior to the metastasis assay, the viability of B16-BL6 incubated with synthetic hybrids was examined and the results are shown in Fig. 4 . Previous studies indicated that aaPEG was not cytotoxic 8) and the data in Fig. 4 indicates that the synthetic hybrids are not cytotoxic.
The inhibitory effect of the hybrids on experimental metastasis in mice was examined and the results are shown in Fig. 5 . B16-BL6 cells and the hybrids were intravenously administered as separate injections to mice. Separate injections may increase the variability in response, but will best isolate the anti-metastatic effect of the sample, avoiding other antimetastatic factors. The mice were sacrificed 14 d after tumor inoculation, and the lungs were removed. The number of surface melanoma colonies on the lungs was counted with a stereoscopic microscope. As shown in Fig. 5 , when compared to control values, hybrids appear to have a dose-dependent inhibitory effect. Although RGD, which is an inhibitor of experimental metastasis, did not show an inhibitory effect at a dose of 3 mg(5.33 mmol)/mouse, PHSRN-aaPEG-RGD and aaPEG-RGD did show a similar inhibitory effect at 3 mg/mouse. Since each 3 mg of PHSRN-aaPEG-RGD and aaPEG-RGD corresponds to 0.67 mmol and 0.78 mmol, the inhibitory effect of RGD is potentiated by the PEG-hybrid formation. These results are comparable to previous studies of PEG-hybrid formation with RGD. 5) Although significant difference in cell spreading activity was observed, a significant difference in the anti-metastatic effect between PHSRN-aaPEG-RGD and aaPEG-RGD was not observed. The relationship between the anti-metastatic effect and cell spreading activity of RGD is not explained by these results. The potentiation of anti-metastatic effect of RGD by PEGhybrid formation may be in part due to a longer half-life in blood.
24) Stability of RGD to enzymatic degradation in blood may be increased by PEG-hybrid formation.
Based upon these studies, aaPEG will be a useful material not only to prepare a bivalent PEG-hybrid, but also to prepare a multivalent PEG-hybrid and a multifunctional PEG-hybrid of biological peptides.
Experimental
Acid hydrolyses were performed in constant-boiling HCl at 110°C for 24 h in evacuated tubes. Amino acid compositions of acid hydrolysates were determined with a Waters Pico · TAG amino acid analyzer and reversed phase (RP)-HPLC was performed using a Waters 600 with a DAISOPAK column and gradient systems of CH 3 CN/water containing 0.05% TFA. TOFmass spectra were obtained from a SHIMADZU/KRATOS KOMPACT MALDI IV spectrometer. 1 H-NMR spectra were obtained on a Brucker DPX-400 (400 MHz) spectrometer. Rink amide resin, protected amino acids and coupling reagents were purchased from Watanabe Chemical Industries, Ltd. TentaGel-NH 2 resin was purchased from Bio-Medical System, Shimadzu Scientific Research Inc. According to the manufacturer, the average molecular weight of the PEG portion of TentaGel-NH 2 is approximately 3000.
General Procedure for Peptide Synthesis by the Manual Solid Phase Method Peptides and hybrids were synthesized on Rink amide or TentaGel-NH 2 resin by a manual method according to the procedure shown below. Coupling reactions were checked by the Kaiser test (ninhydrin test). 21) Step Reagents Reaction time 1 Fmoc-amino acid (3 eq) in DMF 1 h 1 M DIC/DMF (3 eq) in DMF 1 M HOBt (3 eq) in DMF 2 DMF 2 minϫ7 3 20% piperidine/DMF 3 minϫ3 20 minϫ1 4 DMF 2 minϫ7 H-aaPEG-Arg-Gly-Asp-NH 2 Fmoc-aaPEG-Arg(Pmc)-GlyAsp(OBu t )-Rink amide resin was prepared from 330 mg of Rink amide resin (amino content 0.11 mmol) following the above procedure (manual method). Fmoc-aaPEG-OH was preincubated with DIC and HOBt at 0°C for 1 h and allowed to be used in a coupling reaction. Since reaction of Fmoc-aaPEG-OH (3 eq) was slow, it was reacted with H-Arg(Pmc)-GlyAsp(OBu t )-Rink amide resin for 10 h and the reaction was repeated once. Then the Fmoc group was removed with 20% piperidine/DMF and the resulting resin (580 mg) was treated with a mixture of TFA/thioanisole/ ethanedithiol (94/3/3) at room temperature for 2 h. The resin was removed by filtration and the TFA was removed by evaporation. The residue was washed with ether (3 times) and ethyl acetate (3 times), and dried. The mate- /ml) and samples (10 mg/ml) were admixed at the ratio of 1 to 1, and incubated at room temperature. After 60 min, the cells were seeded onto culture dishes, and colonies were counted after 1 week. Each value represents the meanϮS.E. Fig. 5 . In Vivo Anti-metastatic Activity of PEG Hybrids B16-BL6 melanoma cells (1ϫ10 5 /0.1 ml) and a synthetic PEG hybrid (1 mg/0.1 ml/ mouse) were intravenously injected separately into C57BL/6 mice. The mice were killed at 14 d after tumor inoculation, and the lungs were removed. The number of surface melanoma colonies on the lungs was counted under a stereoscopic microscope. Each value represents the meanϮS.E.
